Business
AstraZeneca chief quits CSL board over $50 billion acquisition – Sydney Morning Herald
AstraZeneca’s Pascal Soriot will depart the CSL board next month to prevent potential conflicts of interest after his company bought a US immunology startup.
AstraZeneca announced its planned acquisition of Alexion for $US39 billion ($50.4 billion) in the second week of December, with Mr Soriot telling his investors the deal would allows us to enhance our presence in immunology.
Based in Boston, Alexion develops treatments for rare diseases including in the blood and heart conditions, where CSL is a major player.
CSL, which is producing doses of AstraZenecas COVID-19 vaccine in Australia, told investors last year that Mr Soriots appointment did not look…
-
Business14 hours agoWarning! These ASX 200 shares were just downgraded
-
General22 hours agoSergio Perez and Valtteri Bottas to return to Formula 1 with Cadillac
-
Business12 hours ago2 monthly payers you’ll want to own in 2025 and beyond
-
General23 hours agoTelco Exetel fined $694K after scammers bypass verification processes, access bank accounts